LONDON, April 17, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces it has acquired the FDA-approved Abbreviated New Drug Application ...
The latest update on Hikma Pharmaceuticals focuses on the price target, with the modelled fair value held at 22.14 while core assumptions around discount rate, revenue growth and net profit margin are ...
MORRISTOWN, N.J.--(BUSINESS WIRE)-- Melinta Therapeutics (Melinta) and Hikma Pharmaceuticals PLC (Hikma) today announced they have entered into an exclusive licensing agreement for Vabomere® ...
Builds on company's growing position in Canadian sterile injectables market LONDON, March 9, 2023 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces ...
London, 28 May 2014 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announces that it has signed an asset ...
Hikma Pharmaceuticals has been selling generic drugs globally for 40 years. But it’s also been acquiring companies and building out capabilities, and it's amassed a bevy of brands and employees around ...
Cosmo and Hikma Sign License Agreement for Winlevi® in 17 Middle Eastern and North African Countries
Dublin, Ireland – 02 October 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (“Hikma”) today announced the ...
LONDON, May 1, 2019 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable) the multinational pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results